Table 1.
Baseline characteristics of the study population
| Characteristics | Derivation group (n = 336) |
Validation group (n = 415) |
|---|---|---|
| Age, (mean ± SD) y | 68.67 ± 6.61 | 58.28 ± 10.13 |
| Male sex, n (%) | 232 (69.05) | 328 (79.04) |
| BMI, (mean ± SD) kg/m2 | 25.34 ± 3.33 | 25.94 ± 3.56 |
| Cardiovascular risk factors | ||
| Smoking, n (%) | 139 (41.37) | 238 (57.35) |
| Hypertension, n (%) | 220 (65.48) | 241 (58.07) |
| Hyperlipidemia, n (%) | 103 (30.65) | 121 (29.16) |
| Diabetes mellitus, n (%) | 112 (33.33) | 151 (36.39) |
| Other medical history | ||
| Prior MI, n (%) | 52 (15.48) | 106 (25.54) |
| Prior PCI, n (%) | 71 (21.13) | 108 (26.02) |
| Prior CABG, n (%) | 4 (1.19) | 3 (0.72) |
| Arrhythmia, n (%) | 24 (7.14) | 17 (4.10) |
| Clinical diagnosis | ||
| STEMI, n (%) | 35 (10.42) | 35 (8.43) |
| NSTEMI, n (%) | 25 (7.44) | 29 (6.99) |
| UA, n (%) | 231 (68.75) | 270 (65.06) |
| Undergoing PCI, n (%) | 179 (53.27) | 368(88.67) |
| Number of diseased vessels | ||
| 1-vessel disease, n (%) | 44 (13.10) | 129 (31.08) |
| 2-vessel disease, n (%) | 42 (12.50) | 115 (27.71) |
| 3-vessel disease, n (%) | 92 (27.38) | 80 (19.28) |
| Comorbidities | ||
| Renal insufficiency, n (%) | 14 (4.17) | 10 (2.41) |
| History of stroke, n (%) | 29 (8.63) | 30 (7.23) |
| Laboratory examination | ||
| LVEF, median (IQR) % | 58.00 (52.00,63.00) | 58.00 (52.00,63.00) |
| Creatinine, median (IQR) μ mol/L | 79.55 (69.00,93.85) | 78.80 (69.90,91.60) |
| Concomitant medication | ||
| Tirofiban, n (%) | 153 (45.54) | 210 (50.60) |
| PPI, n (%) | 183 (54.46) | 228 (54.94) |
| Heparin, n (%) | 161 (47.92) | 172 (41.45) |
Abbreviations: BMI Body mass index, MI Myocardial infarction, PCI Percutaneous coronary intervention, CABG Coronary artery bypass grafting, NSTEMI Non-ST-segment elevation myocardial infarction, STEMI, ST-segment elevation myocardial infarction, UA Unstable angina, LVEF Left ventricular ejection fraction, PPI Proton Pump Inhibitor